David P. Nicolau, PharmD

Director
Hartford Hospital
Hartford, Connecticut, United States

Disclosure(s): CARB-X: Grant/Research Support; Innoviva: Grant/Research Support, Honoraria; Merck: Advisor/Consultant, Grant/Research Support, Honoraria; Pfizer: Advisor/Consultant, Grant/Research Support, Honoraria; Shionogi: Advisor/Consultant, Grant/Research Support, Honoraria; Venatorx: Grant/Research Support

Presentation(s):

• 207 - Ex vivo Assessment of Cefepime (FEP) Clearance during Continuous Renal Replacement Therapy (CRRT) and Clinical Validation of Optimized Dosing Regimens

  Thursday, October 17, 2024
  3:15 PM – 3:30 PM US PT

• 511 - Activity of Sulbactam-durlobactam and Standard-of-Care Antibiotics against Acinetobacter baumannii-calcoaceticus complex isolates acquired from Hospitalized Patients in the United States (2023 – 2024)

  Saturday, October 19, 2024
  10:54 AM – 11:06 AM US PT